Ceftolozane/Tazobactam
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nosocomial Pneumonia
Conditions
Nosocomial Pneumonia
Trial Timeline
Apr 17, 2020 → Sep 14, 2024
NCT ID
NCT04223752About Ceftolozane/Tazobactam
Ceftolozane/Tazobactam is a phase 1 stage product being developed by Merck for Nosocomial Pneumonia. The current trial status is completed. This product is registered under clinical trial identifier NCT04223752. Target conditions include Nosocomial Pneumonia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04223752 | Phase 1 | Completed |
| NCT03002506 | Approved | Terminated |
| NCT02620774 | Phase 1 | Completed |
| NCT02421120 | Approved | Completed |
Competing Products
7 competing products in Nosocomial Pneumonia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| levofloxacin; imipenem/cilastitin | Johnson & Johnson | Phase 3 | 77 |
| Ceftazidime-avibactam | AbbVie | Phase 1 | 33 |
| vancomycin monotherapy + daptomycin monotherapy | Novartis | Phase 3 | 77 |
| linezolid | Pfizer | Phase 3 | 76 |
| C Group + E Group | Pfizer | Phase 2/3 | 64 |
| ceftazidim-avibactam (CAZ-AVI, experimental product) + meropenem (active comparator) | Pfizer | Phase 3 | 76 |
| Veronate | Bristol Myers Squibb | Pre-clinical | 22 |